Given the global launch of a corneal inlay (Kamra) for the treatment of presbyopia and an investment by medical technology company Medtronic, AcuFocus says it has experienced significant procedural growth since 2010.
Irvine, CA-Given the global launch of a corneal inlay (Kamra) for the treatment of presbyopia and an investment by medical technology company Medtronic, AcuFocus says it has experienced significant procedural growth since 2010.
“This has been a tremendous year for growth in all areas of our business,” said Ed Peterson, AcuFocus president and chief executive officer.
AcuFocus is selling the intracorneal inlay in Europe, the Middle East, South America, and the Asia-Pacific region. More than 5,000 inlays have been implanted globally.
The company has invested more than 10 years of research and development into the device, with more than 1,000 patients participating in its worldwide clinical trials. The inlay received CE mark approval for use in the European Union in 2005. In the United States, it is considered to be an investigational device under an investigational device exemption.
The intracorneal inlay is designed to create a small aperture effect, allowing the eye to see near and intermediate objects more clearly. By applying the depth-of-focus principle commonly used in photography, the inlay allows only central rays to reach the retina through its fixed 1.6-mm opening.
The inlay is placed under a LASIK-type flap. A proprietary system (AcuTarget, AcuFocus) guides surgeons on proper surgical placement.